The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia

Autor(es)

Uliana, Daniela L. ; Lisboa, Joao Roberto F. ; Gomes, Felipe, V ; Grace, Anthony A.

• Tipo de documento: Artigo Científico
• Fonte: Biochemical Pharmacology; v. 228, p. 13-pg., 2024-09-16.

Resumo

The intricate balance between excitation and inhibition (E/I) in the brain plays a crucial role in normative information processing. Dysfunctions in the E/I balance have been implicated in various psychiatric disorders, including schizophrenia (SCZ). In particular, abnormalities in GABAergic signaling, specifically in parvalbumin (PV)-containing interneurons, have been consistently observed in SCZ pathophysiology. PV interneuron function is vital for maintaining an ideal E/I balance, and alterations in PV interneuron-mediated inhibition contribute to circuit deficits observed in SCZ, including hippocampus hyperactivity and midbrain dopamine system overdrive. While current antipsychotic medications primarily target D2 dopamine receptors and are effective primarily in treating positive symptoms, novel therapeutic strategies aiming to restore the E/I balance could potentially mitigate not only positive symptoms but also negative symptoms and cognitive deficits. This could involve, for instance, increasing the inhibitory drive onto excitatory neurons or decreasing the putative enhanced pyramidal neuron activity due to functional loss of PV interneurons. Compounds targeting the glycine site at glutamate NMDA receptors and muscarinic acetylcholine receptors on PV interneurons that can increase PV interneuron drive, as well as drugs that increase the postsynaptic action of GABA, such as positive allosteric modulators of alpha 5GABA-A receptors, and decrease glutamatergic output, such as mGluR2/3 agonists, represent promising approaches. Preventive strategies aiming at E/I balance also represent a path to reduce the risk of transitioning to SCZ in high-risk individuals. Therefore, compounds with novel mechanisms targeting E/I balance provide optimism for more effective and tailored interventions in the management of SCZ. (AU)

• Processo FAPESP: 18/17597-3 - O impacto do estresse sobre o sistema dopaminérgico é determinado pelo período crítico de plasticidade: implicações para a depressão e a esquizofrenia e o estudo de novos alvos farmacológicos
• Beneficiário: Felipe Villela Gomes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores